Expression of PGDH Correlates with Cell Growth in Both Esophageal Squamous Cell Carcinoma and Adenocarcinoma

  • Yang, Guo-Tao (Department of Thoracic Surgery, Qilu Hospital, Shandong University) ;
  • Wang, Juan (Department of Basic Courses, Shandong University of Science and Technology) ;
  • Xu, Tong-Zhen (Department of Thoracic Surgery, Qilu Hospital, Shandong University) ;
  • Sun, Xue-Fei (Department of Thoracic Surgery, Qilu Hospital, Shandong University) ;
  • Luan, Zi-Ying (Department of Thoracic Surgery, Qilu Hospital, Shandong University)
  • Published : 2015.03.04


Esophageal cancer represents the fourth most common gastrointestinal cancer and generally confers a poor prognosis. Prostaglandin-producing cyclo-oxygenase has been implicated in the pathogenesis of esophageal cancer growth. Here we report that prostaglandin dehydrogenase, the major enzyme responsible for prostaglandin degradation, is significantly reduced in expression in esophageal cancer in comparison to normal esophageal tissue. Reconstitution of PGDH expression in esophageal cancer cells suppresses cancer cell growth, at least in part through preventing cell proliferation and promoting cell apoptosis. The tumor suppressive role of PGDH applies equally to both squamous cell carcinoma and adenocarcinoma, which enriches our understanding of the pathogenesis of esophageal cancer and may provide an important therapeutic target.


  1. Brocklehurst D, Champion AE, Cheek TR, et al (1986). The value of 6-phosphogluconate dehydrogenase (6-PGDH) activity as a marker of tumour cellularity and prognostic indicator in primary breast cancer. Tumour Biol, 7, 99-104.
  2. Castro-Sanchez L, Agra N, Llorente Izquierdo C, et al (2013). Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Int J Biochem Cell Biol, 45, 2501-11.
  3. Chi X, Freeman BM, Tong M, et al (2009). 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal antiinflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys, 487, 139-45.
  4. Dabrowski A, Kwasniewski W, Skoczylas T, et al (2012). Incidence of human papilloma virus in esophageal squamous cell carcinoma in patients from the Lublin region. World J Gastroenterol, 18, 5739-44.
  5. Ding Y, Tong M, Liu S, et al (2005). NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis, 26, 65-72.
  6. Doll CM, Winter K, Gaffney DK, et al (2012). COX-2 Expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer.
  7. Fedeli U, Schievano E, Lisiero M (2012). Mortality after esophageal and gastric cancer resection. World J Surg, 36, 2630-6.
  8. Garewal HS, Sampliner RE, Fennerty MB (1992). Chemopreventive studies in Barrett's esophagus: a model premalignant lesion for esophageal adenocarcinoma. J Natl Cancer Inst Monogr, 51-4.
  9. Gonzalez L, Magno P, Ortiz AP, et al (2012). Esophageal cancer incidence rates by histological type and overall: Puerto Rico versus the United States Surveillance, Epidemiology, and End Results population, 1992-2005. Cancer Epidemiol, 37, 5-10.
  10. Guo P, Li K (2012). Trends in esophageal cancer mortality in China during 1987-2009: age, period and birth cohort analyzes. Cancer Epidemiol, 36, 99-105.
  11. Ho MY, Liang SM, Hung SW, et al (2012). MIG-7 controls COX-2/PGE2-mediated lung cancer metastasis. Cancer Res.
  12. Katkoori V, Manne K, Vital-Reyes V, et al (2012). Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem.
  13. Lee HJ, Yang DH, Ryu YM, et al (2013). 15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms. J Korean Med Sci, 28, 1154-60.
  14. Li L, Yang F, Wang X, et al (2014). Effect of 15-hydroxyprostaglandin dehydrogenase gene on the proliferation of gastric cancer cell murine forestomach carcinoma. Exp Ther Med, 7, 290-4.
  15. McKenna F, Weaver A, Fiechtner JJ, et al (2001). COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol, 7, 151-9.
  16. O'Kane SL, Eagle GL, Greenman J, et al (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67, 160-5.
  17. Roberts HR, Smartt HJ, Greenhough A, et al (2011). Colon tumour cells increase PGE (2) by regulating COX-2 and 15- PGDH to promote survival during the microenvironmental stress of glucose deprivation. Carcinogenesis, 32, 1741-7.
  18. Schaefer M, DeLattre M, Gao X, et al (2005). Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr Med Res Opin, 21, 47-60.
  19. Shan Y, Zhang L, Bao Y, et al (2012). Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem, 24, 1062-9.
  20. Siegel R, Ward E, Brawley O, et al (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.
  21. Silva DR, Curado MP, de Oliveira JC (2012). High incidence of esophageal cancer in central-western Brazil: a migrant effect? Eur J Cancer Prev.
  22. Solomon DH, Schneeweiss S, Levin R, et al (2004). Relationship between COX-2 specific inhibitors and hypertension. Hypertension, 44, 140-5.
  23. Song QK, Li J, Jiang HD, et al (2012). Esophageal cancer mortality during 2004-2009 in Yanting County, China. Asian Pac J Cancer Prev, 13, 5003-6.
  24. Tai HH, Tong M, Ding Y (2007). 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat, 83, 203-8.
  25. Thill M, Becker S, Fischer D, et al (2009). Expression of prostaglandin metabolising enzymes COX-2 and 15-PGDH and VDR in human granulosa cells. Anticancer Res, 29, 3611-8.
  26. Thill M, Fischer D, Kelling K, et al (2010). Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX- 2) and 15-hydroxyprostaglandin dehydrogenase (15- PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol, 121, 387-90.
  27. Walker DI, Eisen V (1979). Effect of ionizing radiation on 15-hydroxy prostaglandin dehydrogenase (PGDH) activity in tissues. Int J Radiat Biol Relat Stud Phys Chem Med, 36, 399-407.
  28. Wang Z, Fan Z, Jiang H, et al (2012). Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis.
  29. Wolfe F, Michaud K, Burke TA, et al (2004). Longer use of COX- 2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol, 31, 355-8.
  30. Young AL, Chalmers CR, Hawcroft G, et al (2013). Regional differences in prostaglandin E (2) metabolism in human colorectal cancer liver metastases. BMC Cancer, 13, 92.
  31. Zhang H, Li X, Ding J, et al (2012). Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm, 441, 261-8.
  32. Zhao SZ, Wentworth C, Burke TA, et al (2004). Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and nonspecific NSAIDs. Pharmacoepidemiol Drug Saf, 13, 277-87.

Cited by

  1. A nonrandomized trial of vitamin D supplementation for Barrett’s esophagus vol.12, pp.9, 2017,
  2. Role of prostanoids in gastrointestinal cancer vol.128, pp.7, 2018,